HENDERSON, Nev.--(BUSINESS WIRE)--Scientists and researchers continue to make astounding advances in personalized medicine, developments that Rainbow Coral Corp. (OTCQB: RBCC) believes will help the company someday market and distribute precision treatments derived from adult stem cells and compounded pharmaceuticals.
“This research will add to the growing effectiveness of personalized medicine”
The latest innovations come from a team at Canada’s University of British Columbia (UBC). The group has been investigating how a person’s DNA can help perfect and target medicine geared specifically towards his or her ailments. The researchers are testing a group of patients’ saliva to uncover unique genetic variations that can reveal how each individual patient responds to medications. The ultimate goal is to develop commercially viable personalized medicines that can be sold at any pharmacy.
“I see genetic information as a way to prescribe less medication – and more accurately,” Dr. Corey Nislow of UBC’s Faculty of Pharmaceutical Sciences told the Toronto Globe and Mail. So far, UBC researchers and scientists elsewhere have examined how genetic variations impact patient reactions for several popular medications, including antidepressants, cholesterol-lowering statins and blood thinners.
RBCC CEO Kimberly Palmer predicted the UBC breakthrough will have a positive impact on the company’s future ability to market and distribute treatments. “This research will add to the growing effectiveness of personalized medicine,” she said. “And that will make it more acceptable to the public, creating greater demand for treatments shown to work on an uniquely individual level. We intend to be a supplier of these treatments across North America.”
Recently released research predicts personalized medicine will grow to a nearly $2.5 billion industry by 2022, a nearly 150 percent increase over today.
For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Rainbow Coral Corp.
Kimberly Palmer, 702-940-2345
President and CEO
info@rainbowcoral.com
